Last update 17 Nov 2024
G2GBIO, Inc.

G2GBIO, Inc.

Startups
| Private Company|2017|Daejeon, South Korea|
< 10
|
www.g2gbio.com

Overview

Tags

Nervous System Diseases
Skin and Musculoskeletal Diseases
Neoplasms
Small molecule drug
Biological products
Recombinant polypeptide

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases2
Neoplasms2
Endocrinology and Metabolic Disease2
Immune System Diseases1
Infectious Diseases1
Top 5 Drug TypeCount
Small molecule drug5
Biological products3
Recombinant polypeptide1
Biosimilar1
Top 5 TargetCount
GnRHR(Gonadotropin-releasing hormone receptor)2
SCNA(Sodium voltage-gated channel alpha subunits)1
GLP-1R(Glucagon-like peptide 1 receptor)1
AChE(Acetylcholinesterase)1
5α-reductase(Steroid 5 alpha reductase)1

Related

9
Drugs associated with G2GBIO, Inc.
Rivastigmine Tartrate
Target
AChE
Mechanism
AChE inhibitors
Active Org.
Actavis Group PTC ehf. [+15]
Originator Org.
Novartis Pharma AG
Active Indication
Progressive Supranuclear Palsy Atypical [+5]
Inactive Indication
Brain Injuries, Traumatic [+6]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
European Union [+3]
First Approval Date11 May 1998
Ropivacaine Hydrochloride
Target
SCNA
Mechanism
SCNA modulators
Active Org.
Jiali (Shenzhen) Biotechnology Co., Ltd. [+13]
Originator Org.
AstraZeneca PLCAstraZeneca PLC
Active Indication
Pain, Postoperative [+5]
Inactive Indication
Hernia, Inguinal
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date24 Sep 1996
GB-7103
Target
GnRHR
Mechanism
GnRHR modulators
Active Org.
G2GBIO, Inc.G2GBIO, Inc.
Originator Org.-
Active Indication
Prostatic Cancer
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with G2GBIO, Inc.
NCT06127368
/ RecruitingPhase 1
An Open-label, Active-controlled, Parallel and Dose-escalation, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers
NCT06095973
/ RecruitingPhase 1
A Single Center, Single-blind, Randomized, Dose-escalation, Parallel, Placebo and Active-controlled, Single Dose, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GB-6002 Local Infiltration in Healthy Male Adults
NCT05525780
/ CompletedPhase 1
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 Intramuscular Depot and Aricept® Oral Tablets (Pfizer Canada Inc.) in Healthy Male Volunteers
100 Clinical Results associated with G2GBIO, Inc.
Login to view more data
0 Patents (Medical) associated with G2GBIO, Inc.
Login to view more data
100 Deals associated with G2GBIO, Inc.
Login to view more data
100 Translational Medicine associated with G2GBIO, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
2
6
Preclinical
Phase 1
1
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free